Issue: December 2018
November 09, 2018
2 min watch
Save
This article is more than 5 years old. Information may no longer be current.
Clinician discusses drug penetration technology in Inveltys
Issue: December 2018
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN ANTONIO – Walter Whitley, OD, MBA, FAAO, discusses the amplified technology behind Inveltys that helps the drug penetrate the eye.
Inveltys (loteprednol etabonate ophthalmic suspension 1%) is a twice-daily ocular steroid for the treatment of inflammation and pain after ocular surgery to be approved by the FDA.